Brief Definitive Report

The Synaptic Vesicle-associated Protein Amphiphysin Is the 128-kD Autoantigen of Stiff-Man Syndrome with Breast Cancer

By Pietro De Camilli,* Annette Thomas,** Roxanne Cofiell,*
Franco Folli,* Beate Lichte,§ Giovanni Piccolo,¶
Hans-Michael Meinck,† Mario Austoni,** Giuliano Fassetta,¶
Gianfranco Bottazzo,§ David Bates,¶ Niall Cartlidge,¶
Michele Solimena,* and Manfred W. Kilimann§

From the *Department of Cell Biology and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06510; the §Institut für Physiologische Chemie, D-4630 Bochum 1, Germany; the **Istituto Neurologo Mondino, Universita' di Pavia, 27100 Pavia, Italy; the †Neurologische Klinik, University of Heidelberg, D-69120 Heidelberg, Germany; the ***Istituto di Semeiotica Medica, University of Padova, 35100 Padova, Italy; the ¶Divisione Neurologica, Ospedale di Belluno, 32100 Belluno, Italy; the §Department of Immunology, London Hospital Medical College, London E1, 2AD, United Kingdom; and the ¶¶Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne NE1, 4LP, United Kingdom

Summary

Stiff-Man syndrome (SMS) is a rare disease of the central nervous system (CNS) characterized by progressive rigidity of the body musculature with superimposed painful spasms. An autoimmune origin of the disease has been proposed. In a caseload of more than 100 SMS patients, 60% were found positive for autoantibodies directed against the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD). Few patients, all women affected by breast cancer, were negative for GAD autoantibodies but positive for autoantibodies directed against a 128-kD synaptic protein. We report here that this antigen is amphiphysin. GAD and amphiphysin are nonintrinsic membrane proteins that are concentrated in nerve terminals, where a pool of both proteins is associated with the cytoplasmic surface of synaptic vesicles. GAD and amphiphysin are the only two known targets of CNS autoimmunity with this distribution. This finding suggests a possible link between autoimmunity directed against cytoplasmic proteins associated with synaptic vesicles and SMS.

Stiff-Man syndrome (SMS) is a rare disease of the central nervous system (CNS) characterized by progressive rigidity of the body musculature with superimposed painful spasms. An autoimmune origin of the disease has been proposed. In a caseload of more than 100 SMS patients, 60% were found positive for autoantibodies directed against the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD). Few patients, all women affected by breast cancer, were negative for GAD autoantibodies but positive for autoantibodies directed against a 128-kD synaptic protein. We report here that this antigen is amphiphysin. GAD and amphiphysin are nonintrinsic membrane proteins that are concentrated in nerve terminals, where a pool of both proteins is associated with the cytoplasmic surface of synaptic vesicles. GAD and amphiphysin are the only two known targets of CNS autoimmunity with this distribution. This finding suggests a possible link between autoimmunity directed against cytoplasmic proteins associated with synaptic vesicles and SMS.

We have recently described three female patients with SMS and breast cancer and no signs of organ-specific autoimmune diseases. These three patients (referred to henceforth as patients BC-SMS 1, 2, and 3, respectively) were negative for GAD autoantibodies but were positive for autoantibodies directed against a 128-kD neuronal antigen concentrated at synapses (9). We have now identified a fourth patient with both breast cancer and SMS syndrome. This patient (BC-SMS 4, as well, was positive for autoantibodies to the 128-kD protein (this study). The characterization of this autoantigen is crucial to the elucidation of pathogenetic mechanisms in SMS with breast cancer. Recently, a novel synaptic vesicle-associated protein, amphiphysin, was described (10). This protein was identified by screening a chicken brain λgt11 library with antibodies raised against chicken brain synaptic proteins. Amphiphysin, an acidic protein present in chicken as well as in mammalian nervous tissue, was shown by immunocytochemistry to be concentrated in nerve terminals. A large fraction of am-
Amphiphysin is present in cytosolic fractions of brain homogenates but a pool of the protein is recovered in a tightly bound form in highly purified synaptic vesicles, although the protein is not enriched on these organelles (10). Some of the properties of amphiphysin were reminiscent of the properties of the 128-kD antigen (10). Therefore, a detailed comparison of the characteristics of the two proteins was performed. We report here that the 128-kD antigen is amphiphysin.

Materials and Methods

Materials. Three sera of SMS patients affected by breast cancer were previously described (9). These sera, defined BC-SMS 1, 2, and 3, correspond to sera of patients 1, 2, and 3, respectively, of reference 9. Serum BC-SMS 4 is from a new patient with both conditions. A GAD autoantibody-positive human serum is from our caseload of SMS sera (6, 8). Rabbit polyclonal antibodies directed against a β-galactosidase chicken amphiphysin fusion protein were previously described (10). These antibodies were shown to recognize rat amphiphysin (10). Rabbit sera directed against synaptophysin (11) and GAD (serum no. 6799 (12)) were the kind gift of Dr. R. Jahn (Yale University, New Haven, CT), and Drs. Z. Katarova and G. Szabo (Hungarian Academy of Sciences, Szeged, Hungary), respectively. Small-scale lysates of bacteria expressing β-galactosidase chicken amphiphysin fusion proteins were prepared according to reference 13. BT3C and αTC9 cell lines were the kind gift of Drs. D. Hanahan (University of California, San Francisco, CA), S. Efrat (Albert Einstein College of Medicine, New York, New York), and E. Leiter (Jackson Laboratories, Bar Harbor, ME), and PC12 cells were the gift of Dr. L. Greene (Columbia University, New York).

Western Blotting of One- and Two-dimensional Gels. Total rat brain homogenate was prepared as described (6, 14). Postnuclear supernatants of rat tissues and of cell lines were prepared by homogenization in 10 vol of ice-cold 10 mM HEPES buffer, pH 7.4, containing freshly added protease inhibitors (0.1 mM PMSF, 1 μg/ml each of antipain, leupeptin, aprotinin, and pepstatin A) followed by centrifugation at 1,000 g for 10 min at 4°C. For twodimensional gels, a supernatant (S1) was centrifuged at 170,000 g for 2 h at 4°C and the resulting supernatant was analyzed by the procedure described by O'Farrell et al. (15) and modified by Ames and Nikai (16). Western blots were performed as described (6, 14) using 128-antiprotein A. Patient sera were used at the dilution of 1:250.

Cell Fractionation and Triton X-114 Phase Separation. A postnuclear supernatant of rat brain (S1) was prepared as described above. S1 was centrifuged at 36,000 g for 30 min at 4°C. The resulting supernatant (S2) was separated into particulate (P3) and cytosolic (S3) fractions by centrifugation at 170,000 g for 2 h at 4°C. P3 and S3 were extracted in 2% Triton X-114, and insoluble material was removed by centrifugation at 20,000 g for 30 min at 4°C. The soluble material was separated into detergent (D) and aqueous (A) phases as described (17). Volumes loaded in each lane were normalized so that corresponding aliquots of supernatants and pellets (or detergent and aqueous phases) were loaded for each pair of fractions.

Immunoprecipitation. A soluble fraction of rat brain (S3) prepared as described above was extracted in ice-cold 2% Triton X-100, 150 mM NaCl, 10 mM HEPES, pH 7.4, for 2 h. Insoluble material was removed by centrifugation at 20,000 g for 30 min at 4°C. The resulting supernatant was diluted with an equal volume of 150 mM NaCl, 10 mM HEPES, pH 7.4 (buffer A), to a final protein concentration of 1 mg/ml. 900-μl aliquots of extract were precleared as described (5) and used for each immunoprecipitation. For immunoprecipitation, the following additions were made in sequential order: (a) 25 μl human sera (16 h); (b) 20 μl rabbit anti-human IgGs (1.5 h); and (c) 125 μl 50% protein A-Sepharose in buffer A (1.5 h). All incubations were performed at 4°C with rotation. Immunoprecipitated material was recovered and analyzed by Western blotting as described (14).

Results and Discussion

Fig. 1 shows Western blots of total rat brain homogenate demonstrating that the 128-kD antigen, i.e., the protein recognized by the sera of BC-SMS patient (lanes 1–3), has the same electrophoretic mobility in SDS-PAGE as the protein recognized by rabbit serum (lane 4) and affinity-purified antibodies (lane 5) raised against a chicken amphiphysin fusion protein. Chicken amphiphysin was calculated to have a molecular mass of 75,204 daltons, but in SDS-PAGE runs, it had an apparent molecular mass of 115–125 kD (10). This molecular mass is very similar to the one of 128 kD estimated here for the rat protein. Fig. 2 shows that the 128-kD antigen and amphiphysin have an identical isoelectric point of 4.7 in two-dimensional gels. This isoelectric point is similar to the predicted isoelectric point of 4.4, calculated on the basis of the amino acid composition of chicken amphiphysin (10).

The distribution of the 128-kD antigen and of amphiphysin were compared in the course of subcellular fractionation of brain homogenates. As shown in Fig. 3, a and b, both the autoantigen and amphiphysin were present in roughly equal amounts in a cytosolic fraction (S3) and in a particulate fraction (P3) obtained from rat brain. Synaptophysin, an intrinsic membrane protein of synaptic vesicles, was present exclusively in the particulate fraction (P3) (Fig. 3 c), demonstrating that the centrifugation conditions used were sufficient to sediment all membranes. Membrane-bound amphiphysin was previously shown to be recovered in the aqueous phase after Triton X-114 extraction and phase separation (10). As shown in Fig. 3, a and b, both the 128-kD antigen and amphiphysin were completely solubilized by Triton X-114 and were recovered exclusively in the aqueous phase irrespective of whether the extraction was performed on P3 or S3 (Fig. 3, a and b). The effectiveness of phase separation conditions was confirmed by the presence of the bulk of synaptophysin (a protein with
Figure 2. The 128-kD antigen and amphiphysin have identical electrophoretic mobilities in two-dimensional gels. Western blot of two-dimensional gels of a soluble rat brain fraction probed with BC-SMS 1 serum (a) and rabbit antiamphiphysin serum (b). Numbers at the top indicate isoelectric points, numbers at the left indicate molecular mass markers (in kD).

The 128-kD antigen and amphiphysin were found to be immunologically cross-reactive. To prove that antiamphiphysin antibodies recognize the 128-kD antigen, BC-SMS patient sera were used to immunoprecipitate the 128-kD antigen from soluble extracts of rat brain. The presence of amphiphysin in the immunoprecipitate was then analyzed by Western blotting using antiamphiphysin serum. An immunoreactive band with electrophoretic mobility of 128 kD was detected (Fig. 4a, lanes 1-3) while no GAD was recovered in the same immunoprecipitates (Fig. 4b, lanes 1-3) confirming previous results (9). As a control, immunoprecipitation was performed with a SMS patient serum that contained high-titer anti-GAD antibodies (6, 8), but no antibodies against the 128-kD autoantigen. This immunoprecipitate was positive for GAD (Fig. 4b, lane 4), but not for amphiphysin (Fig. 4a, lane 4). Conversely, a protein of 128 kD was detected when an immunoprecipitate obtained with antiamphiphysin serum was immunoblotted with BC-SMS patient sera (not shown). To

Figure 3. The 128-kD antigen and amphiphysin partition similarly in differential centrifugation and Triton X-114 phase separation. Particulate (P1) and cytosolic (S1) fractions of rat brain were extracted in Triton X-114 and centrifuged to obtain a soluble (sol) and an insoluble (ins) fraction. The Triton X-114-soluble material (lanes 1 and 4) was separated into detergent (D, lanes 4 and 9) and aqueous (A, lanes 5 and 10) phases. The fractions were probed by immunoblotting with antiamphiphysin affinity-purified antibodies (Amph-AP), with BC-SMS 1 serum (BC-SMS 1), and with antisynaptophysin serum (Synapt-S). The 128-kD antigen and amphiphysin were recovered in both the cytosolic (S3) and in the particulate (P3) fractions, and exclusively in the Triton X-114 aqueous phase derived from these fractions. Synaptophysin, which is an integral membrane protein with four transmembrane spanning domains, is recovered only in P3 and primarily in the detergent phase derived from the Triton X-114-soluble material obtained from P3.

Figure 4. BC-SMS patient sera immunoprecipitate amphiphysin from rat brain extracts. Immunoprecipitates obtained with the sera of three BC-SMS patients (lanes 1-3) and with the serum of a SMS patient positive for GAD autoantibodies (SMS-GAD) (lane 4) were separated by SDS-PAGE. (a) Immunoblotted with rabbit antiamphiphysin serum (Amph-S); and (b) immunoblotted with the rabbit anti-GAD serum no. 6799 (GADS) (12).

Figure 5. BC-SMS patient sera recognize recombinant amphiphysin. Western blots of three identical gel triplets reacted with sera BC-SMS 2, 3, and 4, as indicated. Lanes 1, bacterial lysate expressing a 165-kD fusion protein of β-galactosidase with a yet unidentified synaptic protein (clone 10.12.1; B. Lichte, and M.W. Kilimann, unpublished observation). Lanes 2, bacterial lysate expressing a 165-kD fusion protein of β-galactosidase-chicken amphiphysin fusion protein (clone amphy-11.3; fusion protein size ~230 kD) (10). Lanes 3, chicken brain total homogenate. Identical results were obtained with serum BC-SMS 1 (not shown). Long and short arrows indicate the mobilities of the chicken amphiphysin fusion protein and of the control fusion protein, respectively. Bands below the major immunopositive bands of lanes 2 most likely represent proteolytic fragments of the fusion protein. An arrowhead points to chicken brain amphiphysin.
conclusively demonstrate that BC-SMS sera recognize amphiphysin, they were tested against bacterial lysates containing recombinant amphiphysin as shown in Fig. 5. BC-SMS sera labeled β-galactosidase–chicken amphiphysin fusion protein (Fig. 5, lanes 2) and chicken brain amphiphysin (Fig. 5, lanes 3), but not a control fusion protein (Fig. 5, lanes 1).

Amphiphysin was previously shown to have a restricted tissue distribution (10). Amphiphysin mRNA was detected at high levels in brain and at lower levels in adrenal gland. By immunoblotting amphiphysin was detected in the anterior and posterior pituitary as well (10). The expression of amphiphysin was compared with that of the 128-kD antigen in a variety of tissues and cell lines using Western blotting. Fig. 6 shows that the serum of a BC-SMS patient and the rabbit serum directed against amphiphysin label a similar protein in brain, pituitary, and cell lines derived from adrenal chromaffin cells (PC12 cells) and from pancreatic α and β cells (αTC9, βTC3) (19, 20) but not in liver. Presence of amphiphysin in all cells of pancreatic islets was confirmed by immunocytochemistry (not shown). Endocrine cells of the anterior pituitary, adrenal medulla, and pancreatic islets have many biochemical and functional similarities to neurons and contain organelles closely related to neuronal synaptic vesicles (21, 22). In addition, both amphiphysin and the 128-kD antigen were detected in the tests (Fig. 6). By immunocytochemistry with BC-SMS sera, amphiphysin immunoreactivity in the tests was found to be confined to germ cells. All germ cells expressed amphiphysin irrespective of their stage of differentiation (from spermatogonia to mature spermatozoa) (not shown). Previously, amphiphysin mRNA could not be detected in chicken testis (10), but this was probably so because the RNA had been purified from immature testis of 7-d-old animals. It should be noted that GAD as well is expressed in male germ cells (23). These data convincingly demonstrate that the 128-kD antigen is amphiphysin. Amphiphysin contains in its sequence a hydrophobic 21-amino acid region that would be competent to form a transmembrane helix (10). However, the recovery of amphiphysin both in soluble and membrane fractions (10) as well as the presence of a pool of the protein detectable by immunocytochemistry throughout the neuronal cytoplasm (9) indicate that amphiphysin is not an intrinsic membrane protein. Like amphiphysin, GAD, the other major autoantigen of SMS, is concentrated in nerve terminals where it interacts with synaptic vesicles but is not an intrinsic membrane protein (14, 24–26). While GAD is expressed only by GABA-secreting neurons, amphiphysin is not restricted to these neurons (9, 10).

The similar subcellular localization of GAD and amphiphysin is intriguing if one considers that they are the only two known targets of CNS autoimmunity with this distribution. This observation raises the possibility that pathogenetic mechanisms in SMS may be linked to CNS autoimmunity directed against presynaptic components that interact with synaptic vesicles. Autoantibodies directed against GAD and amphiphysin are not likely to be directly pathogenetic because antibodies are not thought to have access to the cytoplasmic compartment. They may represent the dominant autoantibody species in the context of an autoimmune response directed against multiple antigens (27), including proteins exposed at the cell surface that may be the pathogenetic targets of the autoimmune response. Alternatively, these autoantibodies may reflect an autoimmune reaction in which T cells are the primary players. GAD and amphiphysin autoantibodies segregate with two SMS patient subpopulations, each characterized by different associated diseases. GAD autoantibody–positive SMS is often associated with organ-specific autoimmune diseases and primarily insulin-dependent diabetes mellitus (3–7). Amphiphysin autoantibody–positive SMS occurs only in association with cancer (9) and has the characteristics of an autoimmune paraneoplastic syndrome (28, 29). Therefore, the two patterns of autoimmunity are likely to be related to these different associated conditions. Further studies of antiampiphysin autoimmunity and of the function of amphiphysin or amphiphysin-related molecules not only may shed some light on pathogenetic mechanisms in SMS, but may also help in the elucidation of the biology of at least some types of cancer. Although amphiphysin was not detected in breast cancer tissue (9), it will be of interest to determine whether amphiphysin-related proteins are expressed in breast cancer.

We thank Drs. J. Guarnaccia and K. Marek (New Haven, CT) for reviewing our case load of SMS patients; Drs. D. Hanahan (San Francisco, CA), S. Efrat (New York, NY), E. Leiter (Bar Harbor, ME), L. Greene (New York, NY), Z. Katarova, and G. Szabo (Szeged, Hungary) for the gift of cell lines and antibodies; and Dr. C. David (New Haven, CT) for critical reading of the manuscript.

This work was supported by grants from the National Institutes of Health and by a McKnight Research Project Award (P. De Camilli) and by the Fonds der Chemischen Industrie (M. W. Kilimann). F. Folli was supported by a Dottorato di Ricerca (University of Milano), M. Solimena by the Sydney Blackmer Project Award (P. De Camilli) and by the Fonds der Chemischen Industrie (M. W. Kilimann). F. Folli was supported by a Dottorato di Ricerca (University of Milano), M. Solimena by the Sydney Blackmer
Muscular Dystrophy Association fellowship and by a fellowship from the Juvenile Diabetes Foundation, and A. Thomas by a predoctoral National Institute for Mental Health fellowship. M. W. Killmann is a Heisenberg Fellow of the Deutsche Forschungsgemeinschaft.

Address correspondence to Pietro De Camilli, Howard Hughes Medical Institute, Department of Cell Biology, Boyer Center for Molecular Medicine, 295 Congress Avenue, New Haven, CT 06536-0812. F. Folli’s permanent address is the Department of Medicine, IstitutoScientificoS. Raffaele, Via Olgettina 60, 20100 Milano, Italy, and his present address is the Joslin Diabetes Center, Harvard Medical School, 1 Joslin Place, Boston, MA 02215. B. Lichtle’s present address is the Institut fürBiologie III, Universität Freiburg, D-W-7800, Freiburg, Germany.

Received for publication 8 June 1993 and in revised form 4 August 1993.

References

1. Moersch, F.P., and H.W. Wolman. 1956. Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome): report of a case and some observations in 13 other cases. Mayo Clin. Proc. 31:421.
2. Gordon, E.E., D.M. Januszko, and L. Kaufman. 1967. A critical survey of Stiff-man syndrome. Am. J. Med. 42:582.
3. McEvoy, K.M. Stiff-man syndrome. 1991. Mayo Clin. Proc. 66:300.
4. Blum, P., and J. Jankovic. 1991. Stiff-person syndrome: an autoimmune disease. MovementDis. 6:12.
5. Solimena, M., F. Folli, S. Denis-Donini, G.C. Comi, G. Pozza, P. De Camilli, and A.M. Vicari. 1988. Autoantibodies to glutamic acid decarboxylase in a patient with Stiff-man syndrome, epilepsy, and type I diabetes mellitus. N. Engl. J. Med. 318:1012.
6. Solimena, M., F. Folli, R. Aparisi, G. Pozza, and P. De Camilli. 1990. Autoantibodies to GABA-ergic neurons and pancreatic beta-cells in Stiff-man syndrome. N. Engl. J. Med. 322:1555.
7. Solimena, M., and P. De Camilli. 1991. Autoimmunity to glutamic acid decarboxylase (GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci. 14:452.
8. Butler, M., M. Solimena, R. Dirkx, A. Hayday, and P. De Camilli. 1993. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in Stiff-Man syndrome. J. Exp. Med. 178:2097.
9. Folli, F., M. Solimena, R. Čoffel, M. Austoni, G. Tallini, G. Fassetta, D. Bates, N. Carcchiade, G.F. Bottazzo, G. Piccolo, and P. De Camilli. 1993. Autoantibodies to a 128kD synaptic protein in three women with the Stiff-man syndrome and breast cancer. N. Engl. J. Med. 328:546.
10. Lichtle, B., R.W. Veh, H.E. Meyer, and M.W. Killmann. 1992. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO (Eur. Mol. Biol. Organ.) J. 11:2521.
11. Navone, E., R. Jahn, G. Di Gioia, H. Stukenbrok, P. Green- gard, and P. De Camilli. 1986. Protein p38: an integral membrane protein specific for small vesicles of neurons and neuroendocrine cells. J. Cell Biol. 103:2511.
12. Katarova, Z., G. Szabo, E. Muggaini, and R.J. Greenspan. 1989. Molecular identification of the 62 kD form of glutamic acid decarboxylase from the mouse. Eur. J. Neurosci. 2:190.
13. Carroll, S.B., and A. Laughon. 1987. DNA Cloning. Vol. III. D.M. Glover, editor. IRL Press Ltd., Eynsham, UK. 89-111.
14. Reetz, A., M. Solimena, M. Matteoli, F. Folli, K. Takei, and P. De Camilli. 1991. GABA and pancreatic β-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggest their role in GABA storage and secretion. EMBO (Eur. Mol. Biol. Organ.) J. 10:1275.
15. O’Farrell, P.A., H. Goodman, and P.H. O’Farrell. 1977. Resolution of two dimensional electrophoresis of basic, as well as, acidic proteins. Cell. 12:1133.
16. Ames, B.F., and K. Nikaico. 1976. Two-dimensional gel electrophoresis of membrane proteins. Biochemistry. 15:616.
17. Bordier, C. 1981. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 256:1604.
18. Sudhof, T.C., F. Lottspeich, P. Greengard, E. Mehl, and R. Jahn. 1987. A synaptic vesicle protein with a novel cytoplasm domain and four transmembrane regions. Science (Wash. DC). 238:1142.
19. Efrat, S., S. Linde, H. Kofod, D. Spector, M. Delannoy, S. Grant, D. Hanahan, and S. Bækkelskov. 1988. Beta-cells derived from transgenic mice expressing a hybrid insulin gene- oncogene. Proc. Natl. Acad. Sci. USA. 85:9037.
20. Hamaguchi, K., and E.H. Leiter. 1990. Comparison of cytokine effects on mouse alpha-cell and beta-cell lines. Diabetes. 39:415.
21. De Camilli, P., and R. Jahn. 1990. Pathways to regulated exocytosis in neurons. Annu. Rev. Physiol. 52:625.
22. De Camilli, P. 1991. Co-secretion of multiple signal molecules from endocrine cells via distinct exocytotic pathways. Trends Pharmacol. Sci. 12:446.
23. Persson, H., M. Pelto-Huikko, and M. Metss. 1990. Expression of the neurotransmitter synthesizing enzyme glutamic acid decarboxylase in male germ cells. Mol. Cell. Biol. 10:4701.
24. Erlander, M.G., N.J.K. Tillakaratne, S. Feldblum, N. Patel, and A.J. Tobin. 1991. Two genes encode distinct glutamate decarboxylases. Neuron. 7:91.
25. Christgau, S., H.-J. Aanstoot, H. Schierbeck, K. Begley, S. Tulin, K. Hejnaja, and S. Bækkelskov. 1992. Membrane anchoring of the autoantigen GAD 65 to microvesicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domain. J. Cell Biol. 118:309.
26. Solimena, M., D. Aggujaro, C. Muntzel, R. Dirkx, M. Butler, P. De Camilli, and A. Hayday. 1993. Association of GAD-65, but not of GAD-67, with the Golgi complex of transfected Chinese hamster ovary cells mediated by the N-terminal region. Proc. Natl. Acad. Sci. USA. 90:3873.
27. Tan, E. M. 1991. Autoantibodies in pathology and cell biology. Cell. 67:841.
28. Posner, J.B., and H.M. Furneaux. 1990. Paraneoplastic syndromes. In Immunologic Mechanisms in Neurologic and Psychiatric Disease. Research Publications: Association for Research in Nervous and Mental Disease. Vol. 68. B.H. Waksman, editor. Raven Press, Ltd., New York. 187–219.
29. Hetzel, D.J., C.R. Stanhope, O’Neill, and V.A. Lennon. 1990. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin. Proc. 65:1558.